The prevalence of COPD is high and suppose one of the first public health problem in the world. It has a high morbidity and mortality and healthcare costs. The economic aspect is directly related to hospitalization, accounting for 45-50% of total expenditure of COPD. Patients with frequent exacerbations generate most of the cost. In these patients, there are not standardized treatments or monitoring in a medium or long term, but it seems reasonable that the combination of various interventions (programs self-care, active role of health professionals in consultations, home programs, group visits, establishment action plans for patients, use of communication technologies or social networks) may improve many patient outcomes. The hypothesis of our work will be to introduce telemedicine platform to establish action plans for the patient, recognition of symptoms and exacerbations, treatments for the exacerbations, training material on COPD, smoking and inhalation therapy, establishment of a fast and fluid communication with pulmonologist, with the purpose of responding to various health problems that patients with COPD (exacerbator phenotype or ACO phenotype) may have. We will study the impact of this tool to reduce the rate income or readmission for the patients with COPD, analyzing it from the perspective of cost-effectiveness.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
120
GROUP 1 (telematic group): These patients will have a tablet connected via internet (Telefónica-e-Health). They have to measure their lung function, temperature, pulse oxymetry and symtoms questionnaire every week. The device (tablet) asks them about possible COPD exacerbation. If the patient has an exacerbation, the device offers them a treatment for this exacerbation and it begins a following of this exacerbation until resolution, every day. The pneumologists will receive an alert in other tablet when the patients have an exacerbation or worsening of their diseases. The period of monitoring is 1 year.
GROUP 2 (conventional group or control group) Patients with a COPD exacerbation can go to their family physicians or emergency services and these physicians will establish a treatment and a monitoring of these exacerbation (conventional group). The period of monitoring is 1 year.
Jaime Corral Peñafiel
Cáceres, Spain
Assess whether a telematic program intervention can decrease the rate of readmissions in patients with COPD, comparing with conventional management.
outcome measure: the rate of readmissions during the study
Time frame: one year
Conducting a cost-effectiveness study that allows us to estimate the incremental cost-effectiveness ratio (ICER) of this patient group compared with the control group.
outcome measure: incremental cost-effectiveness ratio (ICER) between these two arms
Time frame: one year
Compare the quality of life of COPD patients by measuring CAT in study groups
outcome measure: quality of life measured by CAT questionnaire
Time frame: one year
To study the evolution of lung function in both groups after 1 year of follow up.
outcome measure: lung function by spirometry (FEV1/FVC, FVC, FEV1)
Time frame: one year
Analyze the survival at 12 months follow-up in each group.
outcome measure: number of deaths in each group to see the survival in this study
Time frame: one year
Analyze a biomarker predictor of exacerbation severity.
outcome measure: PCR (mg/L)
Time frame: one year
Analyze the inhaler compliance and adherence of treatment in both groups.
outcome measure: Morisky-Green´s scoring
Time frame: one year
Make satisfaction survey patients and caregivers, comparing both study groups.
outcome measure: satisfaction (very satisfied, satisfied, unsatisfied, very unsatisfied)
Time frame: one year
Compare the quality of life of patients by measuring EQ-5D in study groups
outcome measure: EQ-5D questionnaire
Time frame: one year
Analyze a biomarker predictor of exacerbation severity.
outcome measure: fibrinogen (g/L)
Time frame: one year
Analyze a biomarker predictor of exacerbation severity.
outcome measure: leukocytes (mil/mm3)
Time frame: one year
Analyze a biomarker predictor of exacerbation severity.
outcome measure: eosinophils (mil/mm3)
Time frame: one year
Analyze a biomarker predictor of exacerbation severity.
outcome measure: pro-BNP (pg/ml)
Time frame: one year
Analyze a biomarker predictor of exacerbation severity.
outcome measure: cholesterol (mg/dL)
Time frame: one year
Analyze a biomarker predictor of exacerbation severity.
outcome measure: proteins (mg/dL)
Time frame: one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.